Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Elaine Lam and Elizabeth Kessler.

 
Connection Strength
 
 
 
2.903
 
  1. Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 06; 3(6):1004-1012.
    View in: PubMed
    Score: 0.898
  2. Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 12; 17(4):1103-1108.
    View in: PubMed
    Score: 0.650
  3. Kessler ER, Gao D, Flaig TW, Breaker K, Wold M, Wacker M, Lam ET. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol. 2017 03 01; 28(3):668.
    View in: PubMed
    Score: 0.582
  4. Gilbert D, Hu J, Medina T, Kessler ER, Lam ET. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors. Hum Vaccin Immunother. 2023 12 31; 19(1):2207438.
    View in: PubMed
    Score: 0.223
  5. Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res. 2018; 7:307.
    View in: PubMed
    Score: 0.156
  6. Lam ET, Kessler ER, Flaig TW, La Rosa FG. Collision renal cell papillary and medullary carcinoma in a 66-year-old man. Oncology (Williston Park). 2013 Sep; 27(9):893, 896, 898.
    View in: PubMed
    Score: 0.114
  7. Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct; 48(10):633-44.
    View in: PubMed
    Score: 0.107
  8. Wiesen B, Atwell M, Leavitt C, Clark N, Kessler E, Lam E, Flaig T, Kukreja J, Kim S, Maroni P, Cost NG. Use of Peripheral Intravenous Access in Patients Undergoing Chemotherapy for Testicular Cancer. JCO Oncol Pract. 2024 Mar; 20(3):361-369.
    View in: PubMed
    Score: 0.058
  9. Boxley PJ, Smith DE, Gao D, Kessler ER, Echalier B, Bernard B, Ormond DR, Lam ET, Kavanagh BD, Flaig TW. Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort. Clin Genitourin Cancer. 2021 06; 19(3):217-222.e1.
    View in: PubMed
    Score: 0.046
  10. Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 06; 35(6):438-446.
    View in: PubMed
    Score: 0.036
  11. Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol. 2015 Nov-Dec; 5(6):e589-e596.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)